Literature DB >> 8885463

Medetomidine sedation in dogs and cats: a review of its pharmacology, antagonism and dose.

L K Cullen1.   

Abstract

Medetomidine is a relatively new sedative analgesic in dogs and cats but some precautions are required when using it. It is a potent alpha 2-adrenoceptor agonist and stimulates receptors centrally to produce dose-dependent sedation and analgesia and receptors centrally and peripherally to cause marked bradycardia and decrease the cardiac output. While hypotension occurs frequently, higher doses of the sedative can raise the blood pressure due to an affect on peripheral receptors. Slowing of the respiratory rate is a frequent effect of medetomidine with some dogs showing signs of cyanosis. Other actions that follow medetomidine use are slowing of gastrointestinal motility, hypothermia, changes to endocrine function and, occasionally, vomiting and muscle twitching. The clinical use of medetomidine in dogs and cats is discussed. Recommended dose rates are presented along with precautions that should be taken when it is used alone for sedation, as an anaesthetic premedicant or in combination with ketamine, propofol or opioids. Hypoxaemia occurs frequently in dogs given medetomidine and propofol. The actions of medetomidine can be rapidly reversed with the specific alpha 2-adrenoceptor antagonist, atipamezole, which is an advantage because undesirable and sedative actions of medetomidine can be terminated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8885463     DOI: 10.1016/s0007-1935(96)80005-4

Source DB:  PubMed          Journal:  Br Vet J        ISSN: 0007-1935


  21 in total

Review 1.  Perioperative use of selective alpha-2 agonists and antagonists in small animals.

Authors:  Kip A Lemke
Journal:  Can Vet J       Date:  2004-06       Impact factor: 1.008

2.  Evaluation of the muscular relaxant effect of dexmedetomidine or medetomidine in cats.

Authors:  P Scrollavezza; A M Tambella; C Vullo; A Palumbo Piccionello
Journal:  Vet Res Commun       Date:  2009-09       Impact factor: 2.459

3.  Sedative and analgesic effects of medetomidine in beagle dogs infected and uninfected with heartworm.

Authors:  C S Venugopalan; E P Holmes; M P Crawford; M J Kearney; V Fucci
Journal:  Vet Res Commun       Date:  1998-02       Impact factor: 2.459

4.  Skin blood perfusion and cellular response to insertion of insulin pen needles with different diameters.

Authors:  Kezia Ann Præstmark; Casper Bo Jensen; Bente Stallknecht; Nils Berg Madsen; Jonas Kildegaard
Journal:  J Diabetes Sci Technol       Date:  2014-04-17

5.  Effects of brimonidine ingestion on cardiovascular responses and renal function in conscious dogs.

Authors:  S Suwanwipat; C Buranakarl; N Chaiyabutr
Journal:  Vet Res Commun       Date:  2006-12-28       Impact factor: 2.459

6.  Chronic monitoring of lower urinary tract activity via a sacral dorsal root ganglia interface.

Authors:  Abeer Khurram; Shani E Ross; Zachariah J Sperry; Aileen Ouyang; Christopher Stephan; Ahmad A Jiman; Tim M Bruns
Journal:  J Neural Eng       Date:  2017-03-21       Impact factor: 5.379

7.  Clinicophysiological effects of spinally administered ketamine and its combination with xylazine and medetomidine in healthy goats.

Authors:  P Kinjavdekar; G R Singh; H P Aithal; A M Pawde
Journal:  Vet Res Commun       Date:  2007-10       Impact factor: 2.459

8.  Survey of utilization of medetomidine and atipamezole in private veterinary practice in Quebec in 2002.

Authors:  M Johanna Kaartinen; Sophie Cuvelliez; Line Brouillard; Yves Rondenay; Jean Jacques Kona-Boun; Eric Troncy
Journal:  Can Vet J       Date:  2007-07       Impact factor: 1.008

Review 9.  A review of the physiological effects of alpha2-agonists related to the clinical use of medetomidine in small animal practice.

Authors:  Melissa D Sinclair
Journal:  Can Vet J       Date:  2003-11       Impact factor: 1.008

10.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.